Elevated serum nuclear factor erythroid 2-related factor 2 levels contribute to a poor prognosis after acute supratentorial intracerebral hemorrhage: A prospective cohort study

被引:1
|
作者
Wang, Chuan-Liu [1 ]
Yan, Xin-Jiang [2 ]
Zhang, Cheng-Liang [1 ]
Xu, Yan-Wen [1 ]
机构
[1] Wenzhou Med Univ, Quzhou Affiliated Hosp, Quzhou Peoples Hosp, Dept Neurol, Quzhou, Zhejiang, Peoples R China
[2] Wenzhou Med Univ, Quzhou Affiliated Hosp, Quzhou Peoples Hosp, Dept Neurosurg, Quzhou, Zhejiang, Peoples R China
来源
关键词
nuclear factor-erythroid 2-related factor 2; intracerebral hemorrhage; early neurologic deterioration; outcome; severity; mechanism; BRAIN; PROTECTS; OUTCOMES; HEALTH; NRF2; DETERIORATION; EXPRESSION;
D O I
10.3389/fnagi.2022.1014472
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
ObjectiveNuclear factor erythroid 2-related factor 2 (Nrf2) is a key transcriptional factor for antioxidant response element-regulated genes. The purpose of this study was to assess the prognostic role of serum Nrf2 in intracerebral hemorrhage (ICH). Materials and methodsIn this prospective observational study, serum Nrf2 levels of 115 acute supratentorial ICH patients and 115 controls were gaged. Early neurologic deterioration (END) was defined as an increase of four or greater points in National Institutes of Health Stroke Scale (NIHSS) score or death at post-stroke 24 h. A poor outcome was referred to as the post-stroke 90-day modified Rankin scale (mRS) score of 3-6. END and a poor outcome were considered as the two prognostic parameters. ResultsAs compared to controls, serum Nrf2 levels of patients were substantially elevated (P < 0.001), with its levels increasing during the 6-h period immediately, peaking in 12-18 h, plateauing at 18-24 h, and decreasing gradually thereafter (P < 0.05). Serum Nrf2 levels of patients were independently correlated with NIHSS score (t = 3.033; P = 0.003) and hematoma volume (t = 3.210; P = 0.002), independently predicted END (odds ratio 1.125; 95% confidence interval 1.027-1.232; P = 0.011) and poor outcome (odds ratio 1.217; 95% confidence interval 1.067-1.387; P = 0.013), as well as efficiently distinguished END (area under curve 0.771; 95% confidence interval 0.666-0.877; P < 0.001) and poor outcome (area under curve 0.803; 95% confidence interval 0.725-0.882; P < 0.001). Its predictive ability was equivalent to those of NIHSS score and hematoma volume (both P > 0.05), and it also significantly improved their predictive abilities under receiver operating characteristic (ROC) curve (all P < 0.05). ConclusionElevated serum Nrf2 levels are closely correlated with severity, END, and 90-day poor outcome following ICH. Hence, Nrf2 may play an important role in acute brain injury after ICH, and serum Nrf2 may have the potential to serve as a prognostic biomarker of ICH.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Molecular docking analysis of melamine with nuclear factor erythroid 2-related factor 2 and succinate dehydrogenase
    Rai, Nitish
    Chowdhary, Sheemona
    Kumar, Deepak
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    BIOINFORMATION, 2022, 18 (08) : 718 - 723
  • [32] Counteracting role of nuclear factor erythroid 2-related factor 2 pathway in Alzheimer's disease
    Sharma, Veerta
    Kaur, Amarjot
    Singh, Thakur Gurjeet
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 129
  • [33] Myeloid Deletion of Nuclear Factor Erythroid 2-Related Factor 2 Increases Atherosclerosis and Liver Injury
    Collins, Alan R.
    Gupte, Anisha A.
    Ji, Ruirui
    Ramirez, Maricela R.
    Minze, Laurie J.
    Liu, Joey Z.
    Arredondo, Magda
    Ren, Yuelan
    Deng, Tuo
    Wang, Jun
    Lyon, Christopher J.
    Hsueh, Willa A.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2012, 32 (12) : 2839 - +
  • [34] Target Nuclear Factor Erythroid 2-Related Factor 2 in Pulmonary Hypertension: Molecular Insight into Application
    Qin, Yuhan
    Qiao, Yong
    Wang, Dong
    Li, Linqing
    Li, Mingkang
    Yan, Gaoliang
    Tang, Chengchun
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
  • [35] The nuclear factor erythroid 2-related factor 2/p53 axis in breast cancer
    Xia, Lei
    Ma, Wenbiao
    Afrashteh, Ahmad
    Sajadi, Mir Amirhossein
    Fakheri, Hadi
    Valilo, Mohammad
    BIOCHEMIA MEDICA, 2023, 33 (03)
  • [36] Interplay between Nuclear Factor Erythroid 2-Related Factor 2 and Amphiregulin during Mechanical Ventilation
    Reiss, Lucy Kathleen
    Fragoulis, Athanassios
    Siegl, Stephanie
    Platen, Christopher
    Kan, Yuet Wai
    Nautiyal, Jaya
    Parker, Malcom
    Pufe, Thomas
    Uhlig, Ulrike
    Martin, Christian
    Uhlig, Stefan
    Wruck, Christoph Jan
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2014, 51 (05) : 668 - 677
  • [37] Nuclear factor erythroid 2-related factor 2 (Nrf2) as a potential therapeutic target for vitiligo
    Lin, Xiran
    Meng, Xianmin
    Song, Zhiqi
    Lin, Jingrong
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2020, 696
  • [38] Emerging trends and hotspots of Nuclear factor erythroid 2-related factor 2 in nervous system diseases
    Chang, Xue-Qin
    Xu, Ling
    Zuo, Yi-Xuan
    Liu, Yi-Guo
    Li, Jia
    Chi, Hai-Tao
    WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (32)
  • [39] Nuclear Factor Erythroid 2-Related Factor 2 and Its Targets in Skeletal Muscle Repair and Regeneration
    Loboda, Agnieszka
    Dulak, Jozef
    ANTIOXIDANTS & REDOX SIGNALING, 2023, 38 (7-9) : 619 - 642
  • [40] Neuroprotective effect of dimethyl fumarate in stroke: The role of nuclear factor erythroid 2-related factor 2
    Safari, Anahid
    Badeli-Sarkala, Hamzeh
    Namavar, Mohammad Reza
    Kargar-Abarghouei, Elias
    Anssari, Neda
    Izadi, Sadegh
    Borhani-Haghighi, Afshin
    IRANIAN JOURNAL OF NEUROLOGY, 2019, 18 (03) : 108 - 113